Patexia Insight 254: Rankings of Leading ANDA Litigation Attorneys

P
Pedram Sameni
January 8, 2026Pharma & ANDA3 min read

ANDA litigation remains one of the most demanding areas of patent law, where outcomes often hinge on the experience and judgment of individual attorneys. In disputes that determine when a generic drug can enter the market, the role of lead counsel is especially critical. Some attorneys consistently handle a high volume of ANDA cases through complex procedural paths and deliver results across multiple matters.

Today’s insight highlights the top ANDA attorneys in 2025, based on measured activity and performance drawn from recent litigation data. Rather than focusing on reputation, the analysis looks at who is actively involved in ANDA disputes and how often their cases result in successful outcomes.

Key Observations From ANDA Litigation in 2025

To address the demand for clear, data-driven insights into ANDA litigation, Patexia publishes its annual ANDA Litigation Report. The 2025 edition examines the past five years of filings, stakeholders' activity, and case outcomes, highlighting the most engaged practitioners and revealing patterns that define the current state of Hatch-Waxman disputes.

Filing trends: Between July 1, 2020, and June 30, 2025, a total of 1,373 ANDA cases were filed. Annual filings increased from 246 in 2021 to 263 in 2022, remained steady at 262 in 2023, and peaked at 317 in 2024. The first half of 2025 recorded 155 cases, putting the year on track to approach 300 filings, based on the consistent monthly average of 25–27 cases seen in recent years.

Attorney activity: The report evaluated 1,574 attorneys, including 235 local counsel, who were active in at least one ANDA litigation case filed over the past five years. Each attorney was evaluated based on three measures: Activity, Success, and Performance, using Patexia’s established methodology.

Terminations and outcomes: Before the report was published, 965 ANDA cases had been resolved. Of these, 54.8% ended in dismissals (voluntary, settled, or otherwise), 31.1% concluded with a judgment, 3.5% were transferred or remanded, and the remaining cases closed administratively. This demonstrates that most Hatch-Waxman disputes are resolved without a formal court ruling.

Top ANDA Attorneys 2025

The following table highlights a selection of the top ANDA attorneys in 2025, based on their activity and performance in Hatch-Waxman litigation. These attorneys have consistently handled high volumes of cases and achieved strong outcomes, playing a central role in the most contested disputes. Being ranked among the top 30 of 1,574 attorneys places them in the top 2% of all ANDA practitioners.

 

Attorney Law Firm All Cases  Defendant Cases  Plaintiff Cases Rank Category
Bruce M. Wexler Paul Hastings 30 1 29 1 Paul Hastings
Dennies Varughese Sterne, Kessler, Goldstein & Fox 60 18 42 1 Overall Activity Rank
Timothy H. Kratz Kratz & Barry 39 39 0 2 Defendant Activity Rank
Andrew S. Chalson Quinn Emanuel Urquhart & Sullivan 13 0 13 3 Plaintiff Performance Rank
Michael J. Gaertner Buchanan Ingersoll & Rooney PC 28 28 0 4 Defendant Performance Rank
Lance A. Soderstrom Katten Muchin Rosenman 33 33 0 5 Defendant Activity Rank
Seth R. Bowers Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 27 0 27 23 Plaintiff Activity Rank
William Zimmerman Knobbe Martens 18 18 0 27 Defendant Activity Rank
Scott J. Bornstein Greenberg Traurig LLP 10 10 0 27 Defendant Performance Rank

 

Note: The rankings in this table and Patexia’s report are based on a combination of activity (cases handled as plaintiff, defendant, or both) and performance (success in terminated cases) metrics for all ANDA filings between July 1, 2020, and June 30, 2025. Firms are scored and ranked to reflect both their level of involvement and effectiveness in litigation. For a detailed explanation of the methodology, see our full methodology here.

Stay tuned as in the weeks ahead, we’ll turn our focus to the PTAB and CAFC, highlighting key findings from the corresponding reports published.

More insights

Data: FDA Orange & Purple Books · prosecution & litigation metadata · read-only.